Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has been assigned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $82.67.
Several research firms have weighed in on TRHC. TheStreet downgraded shares of Tabula Rasa HealthCare from a “c-” rating to a “d+” rating in a research note on Tuesday, June 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $99.00 price target on shares of Tabula Rasa HealthCare in a research note on Monday, May 13th. BidaskClub raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Piper Jaffray Companies boosted their price target on shares of Tabula Rasa HealthCare from $73.00 to $78.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a research note on Saturday.
Tabula Rasa HealthCare stock traded up $0.80 during mid-day trading on Tuesday, hitting $57.27. The company’s stock had a trading volume of 199,800 shares, compared to its average volume of 370,377. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. The stock has a market cap of $1.28 billion, a PE ratio of 168.50 and a beta of 1.63. The business has a 50 day moving average of $53.54. Tabula Rasa HealthCare has a 12 month low of $40.86 and a 12 month high of $91.16.
In related news, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $47.11, for a total transaction of $376,880.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Brian W. Adams sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. The disclosure for this sale can be found here. Insiders have sold 52,000 shares of company stock worth $2,664,520 in the last quarter. 11.80% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tygh Capital Management Inc. lifted its stake in shares of Tabula Rasa HealthCare by 13.2% in the second quarter. Tygh Capital Management Inc. now owns 106,396 shares of the company’s stock worth $5,312,000 after buying an additional 12,439 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Tabula Rasa HealthCare by 7.8% during the second quarter. State Board of Administration of Florida Retirement System now owns 8,444 shares of the company’s stock valued at $422,000 after purchasing an additional 610 shares during the period. Lisanti Capital Growth LLC lifted its position in Tabula Rasa HealthCare by 119.2% during the second quarter. Lisanti Capital Growth LLC now owns 31,155 shares of the company’s stock valued at $1,556,000 after purchasing an additional 16,945 shares during the period. Everence Capital Management Inc. bought a new position in Tabula Rasa HealthCare during the second quarter valued at approximately $236,000. Finally, Swiss National Bank lifted its position in Tabula Rasa HealthCare by 9.4% during the second quarter. Swiss National Bank now owns 32,600 shares of the company’s stock valued at $1,628,000 after purchasing an additional 2,800 shares during the period. Institutional investors own 86.95% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Recommended Story: Percentage Decliners
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.